Affinage

F7

Coagulation factor VII · UniProt P08709

Round 2 corrected
Length
466 aa
Mass
51.6 kDa
Annotated
2026-04-28
121 papers in source corpus 19 papers cited in narrative 19 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

Coagulation factor VII (FVII) is a vitamin K-dependent serine protease zymogen synthesized in the liver that initiates the extrinsic coagulation cascade upon binding its obligate cofactor tissue factor (TF). The single-chain zymogen contains a Gla domain with 10 gamma-carboxylated glutamic acid residues, two EGF-like domains, and a C-terminal serine protease domain; activation occurs by cleavage at Arg152–Ile153 to yield a disulfide-linked two-chain enzyme (FVIIa) that, in complex with TF on phosphatidylserine-containing membranes, activates factors IX and X with dramatically enhanced catalytic efficiency (PMID:3486420, PMID:2248955, PMID:8598903). Crystal structures of free and TF-bound FVIIa reveal that TF binding remodels an alpha-helix at residues 307–312 and the active-site cleft, explaining allosteric enhancement of substrate recognition (PMID:8598903, PMID:10430872). Beyond hemostasis, FVIIa/TF signaling on keratinocytes induces TF-dependent, thrombin-independent transcription of wound-repair genes including c-fos, IL-1β, and uPAR (PMID:10692465). F7 transcription requires HNF4 binding to a proximal promoter element and is modulated by promoter polymorphisms (-323ins10, -402G>A) and CpG methylation, while mutations disrupting the catalytic domain calcium-binding loop or C-terminal residues cause ER retention and secretion failure, collectively accounting for hereditary FVII deficiency (PMID:22628013, PMID:17292373, PMID:22315437, PMID:11159523, PMID:19822353).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 1986 High

    Cloning of F7 cDNA and characterization of TF binding established FVII as a modular vitamin K-dependent serine protease zymogen that requires tissue factor as an obligate cofactor on phospholipid surfaces for coagulation initiation.

    Evidence cDNA cloning from liver/HepG2 libraries with protein sequencing; reconstituted TF-phospholipid binding assays with stoichiometric and affinity measurements

    PMID:3486420 PMID:3527261

    Open questions at the time
    • Three-dimensional structure of the FVIIa–TF complex not yet determined
    • Mechanism by which TF enhances catalytic activity unknown
    • Relative preference for FIX vs FX activation not quantified
  2. 1987 High

    Determination of the complete F7 gene structure revealed conserved intron-exon organization shared with other vitamin K-dependent coagulation factors, establishing a common evolutionary origin for this protease family.

    Evidence Genomic cloning and DNA sequencing of overlapping clones spanning 12.8 kb

    PMID:3037537

    Open questions at the time
    • Regulatory elements controlling liver-specific expression not defined
    • Functional significance of alternative splicing of prepro-leader not established
  3. 1988 High

    Complete post-translational modification mapping of plasma and recombinant FVIIa confirmed 10 Gla residues essential for calcium/membrane binding and identified glycosylation sites, validating recombinant FVIIa as a faithful therapeutic surrogate.

    Evidence HPLC, amino acid analysis, Edman degradation of plasma-derived and BHK-expressed FVIIa

    PMID:3264725

    Open questions at the time
    • Functional impact of partial gamma-carboxylation at position 10 in recombinant protein not tested
    • Role of individual glycosylation sites in activity or clearance unknown
  4. 1990 High

    Quantitative kinetic analysis demonstrated that FVIIa activates both FIX and FX, with TF and phospholipid dramatically increasing catalytic efficiency, resolving uncertainty about substrate specificity and cofactor requirements.

    Evidence Steady-state kinetics with purified recombinant FVIIa, FIX, and FX under defined calcium/TF/phospholipid conditions

    PMID:2248955

    Open questions at the time
    • Structural basis of substrate discrimination between FIX and FX unresolved
    • In vivo relative contributions of FIX vs FX activation not addressed
  5. 1996 High

    The 2.0-Å crystal structure of the FVIIa–TF complex revealed how TF positions FVIIa in an extended conformation for macromolecular substrate recognition, providing the first atomic-level view of extrinsic pathway initiation.

    Evidence X-ray crystallography of active-site-inhibited FVIIa bound to soluble TF ectodomain

    PMID:8598903

    Open questions at the time
    • Conformation of free FVIIa unknown at atomic resolution
    • How TF allosterically remodels the active site not delineated
  6. 1999 High

    Comparison of free FVIIa structure with the TF-bound form revealed that TF binding remodels the 307–312 alpha-helix and active-site geometry, providing the structural explanation for TF-dependent allosteric activation.

    Evidence X-ray crystallography of Gla-domainless FVIIa at 2.8 Å in the absence of TF

    PMID:10430872

    Open questions at the time
    • Full-length FVIIa with Gla domain not crystallized in the free state
    • Dynamic conformational transitions upon TF binding not captured
  7. 2000 High

    Discovery that the FVIIa–TF complex induces TF-dependent, thrombin-independent gene expression of wound-repair mediators in keratinocytes expanded FVII function beyond coagulation to cell signaling.

    Evidence cDNA array profiling of FVIIa-treated keratinocytes with anti-TF blocking and hirudin controls

    PMID:10692465

    Open questions at the time
    • Intracellular signaling pathway linking TF engagement to transcription not identified
    • Whether PAR cleavage mediates this response not determined
    • In vivo relevance to wound healing not tested
  8. 2001 High

    Demonstration that disruption of the catalytic domain calcium-binding loop causes ER retention and pre-Golgi degradation established that proper folding of the protease domain is a checkpoint for FVII secretion.

    Evidence In vitro expression, pulse-chase, protease inhibitor studies, and molecular modeling of a 15-bp insertion mutant in transfected cells

    PMID:11159523

    Open questions at the time
    • Identity of the ER quality-control machinery responsible for mutant FVII degradation unknown
    • Whether similar retention mechanisms apply to other vitamin K-dependent factors not tested
  9. 2005 High

    Systematic dissection of F7 promoter polymorphisms showed that -323ins10 dominantly suppresses transcription while -402A increases it, defining the cis-regulatory architecture controlling plasma FVII levels.

    Evidence Reporter assays with 15 promoter-haplotype constructs in HepG2 cells

    PMID:17292373

    Open questions at the time
    • Trans-acting factors mediating the -323ins10 effect not identified
    • Chromatin context effects not captured by episomal reporter assays
  10. 2009 High

    Studies of C-terminal truncations and splice-site mutations collectively established that both the C-terminal residues of the catalytic domain and correct exon inclusion (particularly exons encoding the Gla domain and propeptide) are indispensable for FVII secretion and procoagulant function.

    Evidence Systematic C-terminal deletion series with immunofluorescence in CHO-K1 cells; minigene splicing assays in HEK293T cells for splice-site mutations

    PMID:15968391 PMID:19601987 PMID:19822353

    Open questions at the time
    • Structural basis of C-terminal requirement for ER export not resolved
    • Whether truncated FVII forms are targeted by ERAD specifically not shown
  11. 2012 Medium

    Identification of HNF4 as an essential transactivator of F7 and demonstration that promoter CpG methylation inversely regulates plasma FVII levels established dual transcriptional and epigenetic control of F7 expression in the liver.

    Evidence EMSA/reporter assays showing HNF4-binding mutations cause lethal FVII deficiency; bisulfite sequencing correlating methylation with FVII levels in 253 subjects

    PMID:22315437 PMID:22628013

    Open questions at the time
    • Causal role of methylation not proven by intervention experiments
    • Other hepatic transcription factors contributing to F7 regulation not systematically mapped
    • Methylation findings from a single cohort study
  12. 2023 Medium

    Functional and molecular-dynamics analysis of novel missense mutations distinguished type I (secretion-defective) from type II (activity-defective) FVII deficiency and identified Gly432 as critical for the FVIIa–TF binding interface.

    Evidence In vitro expression with antigen/activity assays and molecular dynamics simulations of eight F7 missense mutations

    PMID:36951360

    Open questions at the time
    • Computational binding energy predictions not validated by direct binding measurements
    • Structural predictions based on modeling, not experimental structures of mutant proteins
  13. 2024 Medium

    A synonymous exonic variant at the terminal nucleotide of exon 3 was shown to cause exon skipping, demonstrating that silent mutations in F7 can be pathogenic through disruption of splicing regulatory elements.

    Evidence Minigene splicing assay confirming exon 3 skipping caused by c.291G>A

    PMID:39007454

    Open questions at the time
    • Exonic splicing enhancer element disrupted by this variant not precisely mapped
    • Quantitative effect on FVII protein levels in patient hepatocytes not measured

Open questions

Synthesis pass · forward-looking unresolved questions
  • The intracellular signaling pathway by which FVIIa–TF engagement drives gene expression (e.g., whether PAR2 cleavage is involved), the ER quality-control machinery responsible for misfolded FVII degradation, and the full chromatin-level regulatory landscape of F7 transcription in hepatocytes remain unresolved.
  • Signal transduction pathway downstream of FVIIa–TF in non-coagulant signaling not defined
  • ERAD components targeting misfolded FVII not identified
  • No genome-wide chromatin accessibility or enhancer mapping for F7 locus in primary hepatocytes

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 3 GO:0016787 hydrolase activity 2
Localization
GO:0005576 extracellular region 3 GO:0005783 endoplasmic reticulum 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-109582 Hemostasis 4 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 1
Partners
F10F3F9HNF4ASP1
Complex memberships
FVIIa–tissue factor complex

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1986 Human factor VII (FVII) was characterized from cDNA: it is synthesized with a prepro-leader sequence, the mature plasma protein is a 406-amino-acid single-chain polypeptide activated by cleavage between Arg and Ile to form a light chain (152 aa, containing Gla and EGF-like domains) and a heavy chain (254 aa, containing the serine protease domain) linked by a disulfide bond. FVII activates factor X and/or factor IX in the presence of tissue factor and calcium. cDNA cloning from human liver and HepG2 libraries, amino acid sequencing Proceedings of the National Academy of Sciences of the United States of America High 3486420
1987 The human F7 gene spans ~12.8 kb and contains 8 essential exons encoding domains conserved among vitamin K-dependent proteins (Gla, EGF-like, serine protease domains). Alternative splicing produces a transcript with an additional exon encoding a larger prepro-leader sequence. The intron positions relative to protein domains are shared with factor IX, factor X, protein C, and prothrombin, indicating a common evolutionary origin. The gene contains five regions of tandem oligonucleotide repeat elements. Genomic cloning, DNA sequencing of two overlapping genomic clones Proceedings of the National Academy of Sciences of the United States of America High 3037537
1988 Human plasma factor VIIa contains 10 gamma-carboxyglutamic acid (Gla) residues at the N-terminus and 2 N-glycosylated asparagines (Asn145 and Asn322). No beta-hydroxyaspartic acid was detected. Recombinant FVIIa from BHK cells had identical protein backbone but partial gamma-carboxylation (9 full, 1 partial) and partial glycosylation at Asn145 (~66%), with nearly identical overall carbohydrate composition to plasma FVIIa. HPLC, amino acid analysis, peptide mapping, automated Edman degradation of plasma and recombinant FVIIa Biochemistry High 3264725
1986 Factor VII/VIIa binds tissue factor (TF) reconstituted into phospholipid vesicles with 1:1 stoichiometry (1 mol enzyme per mol available TF). The zymogen FVII binds TF with only slightly lower affinity than FVIIa (Kd ~13.2 nM vs ~4.54 nM with PC vesicles). Active-site modification with DFP increased binding affinity. Inclusion of phosphatidylserine (PS) in vesicles induced positive cooperativity in binding, consistent with a two-site cooperative binding model where TF acts as at least a dimer. Binding assays with purified bovine TF reconstituted into phospholipid vesicles of defined composition, protease digestion to assess TF orientation Biochemistry High 3527261
1990 Recombinant human factor VIIa activates both factor IX and factor X. In the presence of calcium alone, FVIIa preferentially activates factor IX over factor X (higher initial rates). Addition of phospholipids and tissue factor dramatically enhances activation of both substrates, with tissue factor increasing kcat/Km for factor X activation substantially. Calcium optimum for factor IX activation was ~1–2.5 mM and for factor X ~2.5 mM. Steady-state kinetics of recombinant FVIIa-catalyzed activation of purified factors IX and X under varying calcium, phospholipid, and tissue factor conditions Biochemistry High 2248955
1996 Crystal structure at 2.0 Å of active-site-inhibited FVIIa complexed with the cleaved extracellular domain of tissue factor (TF). FVIIa adopts an extended conformation in the complex. The structure reveals the molecular basis of TF-induced coagulation initiation, showing how TF positions FVIIa for substrate (FIX, FX) recognition and activation. X-ray crystallography at 2.0 Å resolution Nature High 8598903
1999 Crystal structure of Gla-domain-less human FVIIa at 2.8 Å resolution in the absence of tissue factor. Free FVIIa adopts a similar extended conformation to TF-bound FVIIa, but shows structural differences in the active site and a surface-exposed alpha-helix (residues 307–312) at the cofactor recognition site that is distorted in free FVIIa. The binding mode of the active-site inhibitor D-Phe-Phe-Arg methyl ketone differs between free and TF-bound FVIIa, indicating that TF binding influences substrate recognition in the active site. X-ray crystallography at 2.8 Å resolution Proceedings of the National Academy of Sciences of the United States of America High 10430872
2000 Binding of activated FVII (FVIIa) to tissue factor (TF) on human keratinocytes induces gene expression of 24 mRNA species including transcription regulators (c-fos, egr-1, c-myc), growth factors (amphiregulin, hbEGF, CTGF), proinflammatory cytokines (IL-1β, IL-8), and proteins involved in cellular reorganization (RhoE, uPAR, collagenases). This response was abrogated by anti-TF antibodies and unaffected by hirudin, indicating it is TF-dependent and thrombin-independent. cDNA arrays on human keratinocyte cell line treated with FVIIa; antibody blocking experiments The Journal of biological chemistry High 10692465
2001 A homozygous 15-bp in-frame insertion in F7 (duplicating residues Leu213–Asp217) caused FVII:c <1% and FVII:Ag 10%. Molecular modeling showed the insertion is located at a surface loop of the catalytic domain at the calcium-binding site, disrupting calcium binding and protein folding. In vitro expression in transfected cells showed equivalent intracellular FVII antigen levels for wild-type and mutant, but secreted mutant FVII was only 5–10% of wild-type. Pulse-chase studies demonstrated mutant FVII did not accumulate intracellularly; protease inhibitor studies showed partial degradation in the pre-Golgi compartment. DNA analysis, molecular graphics modeling, in vitro transfection/expression, Western blotting, ELISA, pulse-chase studies, inhibitor studies Blood High 11159523
2002 A novel E25K mutation in the F7 gene (located in the propeptide/signal region) produces a dysfunctional FVII molecule: in transiently transfected HEK293 cells, FVII-E25K showed significantly lower coagulant activity in culture media compared to wild-type, while antigen levels were similar, indicating a functional rather than secretion defect. A second mutation, -96C>T in the F7 promoter (double heterozygous with IVS4+1), was shown by EMSA to disrupt binding of the transcription factor Sp1. F7 gene sequencing, transient transfection of HEK293 cells, functional/antigen assays, electrophoretic mobility shift assay (EMSA) British journal of haematology Medium 12472587
2005 In vitro transfection studies in HepG2 cells with 15 F7 promoter constructs carrying different polymorphism combinations showed that the -323ins10 (A2) allele and -122C allele strongly reduced F7 promoter activity, the -402A allele significantly increased promoter activity, and a novel -2989A variant also increased F7 expression. The A2 (decanucleotide insertion) allele had a dominant effect masking the -2989A variant in Spanish populations. In vitro transfection of HepG2 cells with 15 F7 promoter-reporter constructs; functional reporter assays Atherosclerosis High 17292373
2009 A nonsense mutation (p.Arg462X) in F7, causing loss of the five C-terminal amino acids of FVII, resulted in undetectable secretion (by Western blot and ELISA) into culture medium. In vitro expression of truncated FVIIs deleted of limited numbers of C-terminal amino acids showed secretion decreased proportionally with deletion length. Arg462X FVII did not co-localize with the Golgi apparatus on immunofluorescence, suggesting ER retention and intracellular degradation. Expression of truncated FVII variants in CHO-K1 cells, Western blot, ELISA, immunofluorescence colocalization with Golgi marker Thrombosis research High 19822353
2009 A splice site mutation IVS1a+5g>a in F7 causes two novel aberrant splicing patterns: (1) predominant transcript skipping exon 2 but retaining intron 3, causing frameshift and premature stop; (2) minor transcript skipping both exon 2 and exon 3 (FVII Δ2,3), causing in-frame deletion of propeptide and Gla domains. In vitro expression of the FVII Δ2,3 transcript in HEK293 cells showed that the protein could be secreted but had no procoagulant activity. Ectopic transcript analysis in patient leukocytes, F7 minigene construction spanning intron 4 to intron 7 transfected into HEK293T cells, RT-PCR sequencing, in vitro expression Thrombosis and haemostasis High 15968391
2009 A splice site mutation c.572-1G>A in F7 was shown by minigene analysis to cause exon 6 skipping, producing erroneously spliced mRNA, while normal splicing occurred in wild-type transfectant. Ectopic transcription in patient leukocytes did not detect the aberrant transcript, demonstrating the minigene approach is required for genes with poor expression in blood cells. F7 minigene (intron 4 to intron 7) transfected into HEK293T cells, RT-PCR analysis; ectopic transcript analysis in leukocytes Haemophilia Medium 19601987
2012 F7 promoter methylation inversely regulates plasma FVII concentrations in subjects with the A1A1 genotype (absence of the -323ins10 insertion). Higher methylation at the F7 promoter is associated with lower plasma FVII levels and was more prevalent in the coronary-artery-disease-free group compared to CAD subjects, suggesting epigenetic regulation of F7 via promoter CpG methylation modulates cardiovascular risk. Methyl-specific PCR and bisulfite sequencing of F7 promoter in 253 subjects; correlation with plasma FVII activity and CAD status Journal of medical genetics Medium 22315437
2012 Novel F7 promoter mutations (-65G>C single nucleotide substitution and -60_-59delTT 2-bp deletion) causing lethal FVII deficiency were shown to disrupt HNF4 (hepatocyte nuclear factor 4) binding. Computer-assisted analysis predicted disrupted binding of both HNF4 and COUP-TF. Experimental reporter assays confirmed altered HNF4-induced transactivation with each promoter variant. Sequencing of F7 promoter, in silico binding site analysis, functional transactivation reporter assays Thrombosis and haemostasis Medium 22628013
2022 A novel F7 promoter mutation (-58G>C) in the HNF4 binding region caused FVII deficiency (compound heterozygous with p.Leu13Pro). EMSA demonstrated that the -58G>C promoter mutation reduced HNF4 binding, establishing that HNF4 binding to the F7 promoter is required for normal F7 transcription and FVII protein synthesis. F7 gene sequencing, EMSA for transcription factor binding The Kurume medical journal Medium 36123027
2023 Functional and structural analysis of eight novel F7 mutations identified in Chinese patients: three type I missense mutations (p.Cys238Phe, p.Gly420Asp, p.Ala252Val) reduced FVII secretion/antigen; four type II missense mutations (p.Val336Met, p.Ser342Gly, p.Gly432Ser, p.Ile213Asn) affected FVII coagulant activity with relatively preserved antigen. Molecular dynamic simulations and binding energy calculations for p.Gly432Ser revealed that Gly432 is critical for the binding interface between activated FVIIa and tissue factor. Structural analysis confirmed that p.Ile213Asn impacts the cleavage/activation site. In vitro expression, functional coagulant and antigen assays, molecular dynamic simulations, binding energy calculations, structural analysis British journal of haematology Medium 36951360
2024 A synonymous variant at the terminal nucleotide of exon 3 (c.291G>A) in F7, which does not alter the amino acid sequence, was shown by minigene analysis to cause exon 3 skipping, thereby disrupting the protein sequence and function and causing FVII deficiency when compound heterozygous with a splice donor mutation (c.681+1G>T). Whole exome sequencing, Sanger sequencing validation, minigene splicing assay Molecular genetics & genomic medicine Medium 39007454

Source papers

Stage 0 corpus · 121 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
1999 Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature genetics 1381 10391209
2009 Defining the human deubiquitinating enzyme interaction landscape. Cell 1282 19615732
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
1996 The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 670 8598903
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2008 Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 526 18267072
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
1986 Characterization of a cDNA coding for human factor VII. Proceedings of the National Academy of Sciences of the United States of America 398 3486420
2003 The dynamics of thrombin formation. Arteriosclerosis, thrombosis, and vascular biology 387 12524220
1990 Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 381 2271516
1994 The mechanism of inactivation of human factor V and human factor Va by activated protein C. The Journal of biological chemistry 347 7989361
2006 Association of warfarin dose with genes involved in its action and metabolism. Human genetics 299 17048007
2010 Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 295 20231535
1986 Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 290 3527261
1987 Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proceedings of the National Academy of Sciences of the United States of America 287 3037537
2017 Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proceedings of the National Academy of Sciences of the United States of America 282 28611215
1988 Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 278 3264725
2004 An investigation into the human serum "interactome". Electrophoresis 247 15174051
1995 Tissue factor pathway inhibitor and the revised theory of coagulation. Annual review of medicine 233 7598447
2006 Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clinical pharmacology and therapeutics 219 16580898
2011 Toward an understanding of the protein interaction network of the human liver. Molecular systems biology 207 21988832
2014 Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC cancer 203 25037231
2000 Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. The New England journal of medicine 185 10984565
2005 Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thrombosis and haemostasis 183 15735798
2003 No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 177 12615788
1990 Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 176 2248955
2009 Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. American journal of human genetics 164 19913121
2000 Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. The Journal of biological chemistry 157 10692465
1999 Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proceedings of the National Academy of Sciences of the United States of America 147 10430872
1988 The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. Journal of immunological methods 104 2828478
1982 F7 and type 1-like fimbriae from three Escherichia coli strains isolated from urinary tract infections: protein chemical and immunological aspects. Infection and immunity 92 6123483
2020 Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7. Molecular therapy : the journal of the American Society of Gene Therapy 91 33129371
1993 A polymorphism in the 5' region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Human genetics 87 8381388
1992 Detection of two missense mutations and characterization of a repeat polymorphism in the factor VII gene (F7). Human genetics 72 1634227
1993 Serine92 (F7) contributes to the control of heme reactivity and stability in myoglobin. Biochemistry 68 8494890
1994 A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. Journal of immunological methods 61 8083529
2012 Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn(F7/F7) mouse model. Stem cells (Dayton, Ohio) 54 22644669
2012 Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease. Journal of medical genetics 47 22315437
1991 PCR detection of a repeat polymorphism within the F7 gene. Nucleic acids research 44 1886792
2007 Keratinolytic activity of Bacillus megaterium F7-1, a feather-degrading mesophilic bacterium. Microbiological research 40 17459685
1984 Molecular organisation of the genes involved in the production of F7(2) fimbriae, causing mannose-resistant haemagglutination, of a uropathogenic Escherichia coli 06:K2:H1:F7 strain. Molecular & general genetics : MGG 37 6146091
1985 Comparison of the nucleotide sequences of the genes encoding the KS71A and F7(1) fimbrial antigens of uropathogenic Escherichia coli. European journal of biochemistry 36 2992970
2017 Bioactive compounds of Aspergillus terreus-F7, an endophytic fungus from Hyptis suaveolens (L.) Poit. World journal of microbiology & biotechnology 31 28243983
2005 The F7 gene and clotting factor VII levels: dissection of a human quantitative trait locus. Human biology 29 16596941
2013 Isolation and characterization of a Sphingomonas sp. strain F-7 degrading fenvalerate and its use in bioremediation of contaminated soil. Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 26 23356341
2017 F7 gene variants modulate protein levels in a large cohort of patients with factor VII deficiency. Results from a genotype-phenotype study. Thrombosis and haemostasis 25 28447100
2020 F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia. Drug delivery 23 32508162
2016 Quinone/hydroquinone meroterpenoids with antitubercular and cytotoxic activities produced by the sponge-derived fungus Gliomastix sp. ZSDS1-F7. Natural product research 23 27417331
2007 Functional analysis of the genetic variability in the F7 gene promoter. Atherosclerosis 23 17292373
1988 Biogenesis of F71 and F72 fimbriae of uropathogenic Escherichia coli: influence of the FsoF and FstFG proteins and localization of the Fso/FstE protein. Molecular microbiology 23 28776787
1986 Functional relationship among the gene clusters encoding F7(1), F7(2), F9, and F11 fimbriae of human uropathogenic Escherichia coli. Journal of bacteriology 23 2873130
2010 Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis 22 21057703
2012 Isolation and characterization of Streptomyces spp. strains F-6 and F-7 capable of decomposing alkali lignin. Environmental technology 21 23437660
2010 Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. Journal of thrombosis and haemostasis : JTH 19 20735728
2009 Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency. Thrombosis research 17 19822353
2013 Correlation between single nucleotide polymorphism of rs3811047 in IL-1 F7 gene and rheumatoid arthritis susceptibility among Han population in central plains of China. Asian Pacific journal of tropical medicine 16 23317890
1991 Bacteriophage receptors of Lactococcus lactis subsp. 'diacetylactis' F7/2 and Lactococcus lactis subsp. cremoris Wg2-1. FEMS microbiology letters 16 1903350
2009 The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and genomics 14 19415820
1998 In vitro and in vivo evaluation of insulin-producing beta TC6-F7 cells in microcapsules. The American journal of physiology 13 9612223
2009 Using a minigene approach to characterize a novel splice site mutation in human F7 gene causing inherited factor VII deficiency in a Chinese pedigree. Haemophilia : the official journal of the World Federation of Hemophilia 12 19601987
2005 Human F7 sequence is split into three deep clades that are related to FVII plasma levels. Human genetics 12 16292673
2001 Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood 12 11159523
1982 Tests of association of lymphocyte alloantigen genotypes with resistance to viral oncogenesis in chickens. 1. Marek's disease in F7 progeny derived from 6(3) X 15(1) crosses. Poultry science 12 6131413
2019 2-methylquinazoline derivative F7 as a potent and selective HDAC6 inhibitor protected against rhabdomyolysis-induced acute kidney injury. PloS one 11 31639165
1988 Biogenesis of F7(1) and F7(2) fimbriae of uropathogenic Escherichia coli: influence of the FsoF and FstFG proteins and localization of the Fso/FstE protein. Molecular microbiology 11 2897068
2009 Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease. Journal of genetics 10 20086294
2002 Two double heterozygous mutations in the F7 gene show different manifestations. British journal of haematology 10 12472587
1986 Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level. Neurochemistry international 10 20493099
2023 A glucose tolerant β-glucosidase from a newly isolated Neofusicoccum parvum strain F7: production, purification, and characterization. Scientific reports 9 36991150
2022 The structure of AcrIE4-F7 reveals a common strategy for dual CRISPR inhibition by targeting PAM recognition sites. Nucleic acids research 9 35166843
2021 Monocyte Dysfunction Detected by the Designed Ankyrin Repeat Protein F7 Predicts Mortality in Patients Receiving Veno-Arterial Extracorporeal Membrane Oxygenation. Frontiers in cardiovascular medicine 9 34350217
2014 Arrangement of the Clostridium baratii F7 toxin gene cluster with identification of a σ factor that recognizes the botulinum toxin gene cluster promoters. PloS one 9 24853378
2010 The Mediterranean Sea as a barrier to gene flow: evidence from variation in and around the F7 and F12 genomic regions. BMC evolutionary biology 9 20346176
2021 Co-delivery of F7 and crizotinib by thermosensitive liposome for breast cancer treatment. Journal of liposome research 8 34904521
2012 Functional epistatic interaction between rs6046G>A in F7 and rs5355C>T in SELE modifies systolic blood pressure levels. PloS one 8 22815813
2007 Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency. British journal of haematology 8 17614823
2007 Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry. Part A : the journal of the International Society for Analytical Cytology 8 17879237
2003 Prevalence of factor VII deficiency and molecular characterization of the F7 gene in Brazilian patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 8 12695753
1992 Hemoglobin Sabine [beta 91 (F7) Leu-->Pro]: occurrence in a Sardinian individual with hemolytic anemia and inclusion bodies. Haematologica 8 1336469
2012 Combined congenital dysfibrinogenemia and factor VII deficiency from mutations in the FGB and F7 genes. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 7 22576285
2005 Novel aberrant splicings caused by a splice site mutation (IVS1a+5g>a) in F7 gene. Thrombosis and haemostasis 7 15968391
2015 Expression and biochemical characterization of light chains of Botulinum neurotoxin subtypes F5 and F7. Protein expression and purification 6 25858313
2012 Lethal factor VII deficiency due to novel mutations in the F7 promoter: functional analysis reveals disruption of HNF4 binding site. Thrombosis and haemostasis 6 22628013
2023 Structural and functional characterization of novel F7 mutations identified in Chinese factor VII-deficient patients. British journal of haematology 5 36951360
2017 HEREDITARY FACTOR VII DEFICIENCY IN THE ASIAN ELEPHANT (ELEPHAS MAXIMUS) CAUSED BY A F7 MISSENSE MUTATION. Journal of wildlife diseases 5 28118558
2008 HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor. Oncology reports 5 18497949
2006 Genetic architecture of the F7 gene in a Spanish population: implication for mapping complex diseases and for functional assays. Clinical genetics 5 16650081
1990 GDA-J/F7 monoclonal antibody: a new marker for sperm cell precursors in human semen. Journal of reproductive immunology 5 2254877
2019 Coagulant activity of recombinant human factor VII produced by lentiviral human F7 gene transfer in immortalized hepatocyte-like cell line. PloS one 4 31381603
2012 A biodegradation study of forest biomass by Aspergillus niger F7: correlation between enzymatic activity, hydrolytic percentage and biodegradation index. Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] 4 24031853
2010 Screening of IR50 x Rathu Heenati F7 RILs and identification of SSR markers linked to brown planthopper (Nilaparvata lugens Stål) resistance in rice (Oryza sativa L.). Molecular biotechnology 4 20396978
1999 Threonine phosphorylations induced by RX-871024 and insulin secretagogues in betaTC6-F7 cells. The American journal of physiology 4 10567013
1997 Evaluation of immunoisolated insulin-secreting beta TC6-F7 cells as a bioartificial pancreas. Annals of transplantation 4 9869861
1990 [Cloning and expression of Clostridium thermocellum F7 cellulase genes in Escherichia coli and Bacillus subtilis cells]. Genetika 4 2124195
1990 [Cloning and expression of Clostridium thermocellum F7 endoglucanase gene in gram-negative bacteria]. Genetika 4 2258032
2018 Four New C9 Metabolites from the Sponge-Associated Fungus Gliomastix sp. ZSDS1-F7-2. Marine drugs 3 29987219
2014 Immobilization of Aspergillus niger F7-02 Lipase in Polysaccharide Hydrogel Beads of Irvingia gabonensis Matrix. Enzyme research 3 25614829
2007 Clustering of individuals given SNPs similarity based on normalized mutual information: F7 SNPs in the GAIT sample. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 3 18001904
2022 Novel heterozygous F7 gene mutation (c. C1286T) associated with congenital factor VII deficiency: A case report and literature review. Journal of clinical laboratory analysis 2 35349734
2021 Compound Heterozygous Mutations in the F7 Gene in 2 Unrelated Families With Congenital Factor VII Deficiency. Journal of pediatric hematology/oncology 2 33480651
2013 Double heterozygous mutations Gln100Leu and His348Gln of the F7 gene in a patient with factor VII deficiency. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2 23358202
2011 [Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease]. Genetika 2 22232927
1990 Functional analysis of the fsoC gene product of the F7(1) (fso) fimbrial gene cluster. Molecular microbiology 2 1969606
2025 Nutrient consumption patterns of Streptococcus thermophilus F7 under acid stress and their application in enhancing biomass production. Journal of dairy science 1 40306427
2022 Clinical phenotype and F7 gene genotype in 40 Tunisian patients with congenital factor VII deficiency. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1 35802509
2014 Quorum sensing activity of Mesorhizobium sp. F7 isolated from potable water. TheScientificWorldJournal 1 25177734
2009 N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer research 1 19596910
1989 Development of specific human mab's by a small scale electrofusion technique: the influence of some physical and chemical factors on hybridoma yield of human peripheral blood lymphocytes XCB-F7 fusions. Allergie und Immunologie 1 2788981
2025 [Analysis of a Chinese pedigree affected with hereditary factor Ⅶ deficiency due to compound heterozygous variants of F7 gene]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 41451501
2024 [Analysis of three Chinese pedigrees affected with Hereditary factor Ⅶ deficiency due to compound heterozygous variants of F7 gene]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 38565502
2024 [Congenital FⅦ Deficiency Associated with a Novel Mutation in F7 Gene]. Zhongguo shi yan xue ye xue za zhi 0 38926980
2024 Synonymous variant at the terminal nucleotide in exon 3 of F7 causes abnormal splicing: A case report. Molecular genetics & genomic medicine 0 39007454
2024 Frequency and Association of Polymorphisms in F2, F7, and PROS1 Coagulation Genes with Disease Severity in Coronavirus Disease 2019. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 0 39497411
2022 Factor VII Deficiency Due to Compound Heterozygosity for the p.Leu13Pro Mutation and a Novel Mutation in the HNF4 Binding Region (-58G>C) in the F7 Promoter. The Kurume medical journal 0 36123027
2020 [Analysis of a Chinese pedigree affected with hereditary factor VII deficiency caused by compound heterozygous variants of F7 gene]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 32472540
2020 Generation of a human induced pluripotent stem cell line, YCMi002-A, from a Factor VII deficiency patient carrying F7 mutations. Stem cell research 0 33038747
2018 [Analysis of Phenotype and L12R Mutation in Signal Peptide and 3' Non-translation Region c11814-insAA Mutation of F7 Gene in a Family with Hereditary Coagulation Factor VII Deficiency]. Zhongguo shi yan xue ye xue za zhi 0 29665924
2013 [Cloning, expression and identification of Der f7 gene from Dermatophagoides farinae and its immunological characteristics]. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases 0 24818391
2008 SNP sets selection under mutual information criterion, application to F7/FVII dataset. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 0 19163535
1980 F1 hybrid versus 32 selected F7 lines performance of common winter wheat (Triticum aestivum ssp. vulgare). TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik 0 24301286